Aethlon Medical, Inc. · NASDAQ:AEMD
Aethlon Medical — Sequire Biotechnology Conference 2023
20 slides from Aethlon Medical's conference presentation, February 2023
Slide 1: Sequire Biotechnology Conference February 2023
Sequire Biotechnology Conference February 2023 11555 Sorrento Valley Rd, Suite 203 San Diego, California 92121 619.941.0360 Nasdaq: AEMD www.AethlonMedical.com
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This investor presentation contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this presentation are forward-looking statements, including
Slide 3: Aethlon Medical, Inc.
Aethlon Medical, Inc. • Headquartered in San Diego, CA (NASDQ: AEMD) • Focused on combating cancer and infectious diseases with immunotherapeutic technologies • Aethlon’s Hemopurifier has demonstrated the capture of disease promoting exosomes and circulating viruses in clinical trials and emergency
Slide 4: Aethlon's senior management team has extensive experience with both medical devices and therapeutics
Aethlon’s senior management team has extensive experience with both medical devices and therapeutics Companies Charles J. Fisher, Jr., MD, FACP, FCCP, FCCM, Chief Executive Officer • Academic & Industry thought leader in sepsis & inflammation • Head of critical care—Cleveland Clinic • 35 years indus
Slide 5: The Aethlon Hemopurifier
The Aethlon Hemopurifier® FDA designated “Breakthrough Device” • Safely administered in 156 Hemopurifier sessions in 36 patients • Proprietary mechanism of action • Clears life-threatening mannosylated* viruses • Designed to clear mannosylated* tumor-derived exosomes * Mannose is a ”sugar” that coat
Slide 6: The Hemopurifier's unique mechanism of action captures virus and exosomes from a patient's blood
The Hemopurifier’s unique mechanism of action captures virus and exosomes from a patient’s blood via extracorporeal circuit A B (Optional) The Hemopurifier captures enveloped viral pathogens and exosomes in circulating blood C • Hollow-fiber plasma separator filled with proprietary “affinity resin”
Slide 7: Hemopurifier Clinical Pipeline – Safety, Feasibility, Proof of Concept
Hemopurifier Clinical Pipeline – Safety, Feasibility, Proof of Concept Emergency Early Feasibility Indication Pre-Clinical Pivotal Study Use Study Terminated Cancer HNSCC Solid Tumors Expected to begin in failing anti- Australia second half PD-1 of 2023 US COVID-19 Terminated Viral Infection India C
Slide 8: Extensive rationale exists for the removal of tumor-derived exosomes by Aethlon's Hemopurifier to treat cancer
Extensive rationale exists for the removal of tumor-derived exosomes by Aethlon’s Hemopurifier to treat cancer Exosomes are 50-150nm extracellular vesicles that are released by all cell types including tumor cells. Specifically, exosomes: • Communicate with other cells to modulate local and distant
Slide 9: In Vitro removal of cancer-derived exosomes has been demonstrated with a benchtop Hemopurifier
In Vitro removal of cancer-derived exosomes has been demonstrated with a “benchtop” Hemopurifier • A scaled down benchtop version of the Hemopurifier was operated by recirculating samples of cancer patients' plasma through the hollow fiber filters ex vivo • The exosomes remaining in plasma were quan
Slide 10: Demonstrated reduction of total exosomes and harmful cargo in an emergency use COVID-19 patient
Demonstrated reduction of total exosomes and harmful cargo in an emergency use COVID-19 patient treated with Hemopurifier Total Exosomes and Exosomal miRNA over time: miR-424 is associated with COVID-associated miR-16 is associated with acute lung injury coagulopathy (excessive blood clotting) *COVI
Slide 11: Clinical Development: Hemopurifier Treatment for Oncology
Clinical Development: Hemopurifier Treatment for Oncology • Initial Early Feasibility study in head and neck cancer terminated due to lack of patient recruitment - two subjects were enrolled at University of Pittsburgh Medical Center • A new clinical trial in oncology is planned to include more tumo
Slide 12: Recent scientific & clinical literature provide a rationale for Hemopurifier treatment in severe COVID-19 infections
Recent scientific & clinical literature provide a rationale for Hemopurifier treatment in severe COVID –19 infections • COVID viremia is detected in ~34% of patients and is associated with severity, requirement for ICU stay, development of multi-organ failure and poor outcomes • Direct viral injury
Slide 13: COVID-19 US IDE study update
COVID-19 US IDE study update: Treatment of SARS-CoV-2 infection in humans with Hemopurifier device • The FDA approved an Early Feasibility Study • ICU patients with severe or life-threatening disease • 1 patient enrolled • Terminated study due to lack of COVID-19 patients in the ICU • While our Inve
Slide 14: COVID-19 India trial update
COVID-19 India trial update: Treatment of SARS-CoV-2 infection in humans with Hemopurifier device • ICU patients with severe or life-threatening disease • Up to 15 patients at up to 3 centers • 1 patient enrolled and treated • Regulatory agency has approved the use of Hemopurifier devices for clinic
Slide 15: Hemopurifier Clinical Development Summary
Hemopurifier Clinical Development Summary Oncology Viral Infections • Safety, Feasibility and Dose • Clinical Trial of Finding Study in Solid Hemopurifier in Severe Tumors Failing anti-PD-1 COVID-19 infection antibodies • Currently underway in India • To be initiated first in Australia and then in t
Slide 16: US Government funded preclinical studies focused on identifying exosomes in cancer patients
US Government funded preclinical studies focused on identifying exosomes in cancer patients • Phase I contract from NCI — Completed • “Device Strategy for Differential Isolation of Oncosomes* and Non-Malignant Exosomes” • NCI SBIR Grant — Completed • “The Hemopurifier Device for Targeted Removal of
Slide 17: Ongoing preclinical studies to expand potential utility of Hemopurifier
Ongoing preclinical studies to expand potential utility of Hemopurifier • Monkeypox (mPox) • Experiment underway at Battelle Labs to examine the in vitro removal of the currently circulating strain of mPox by a miniature version of the Aethlon Hemopurifier • Post-acute Sequelae of COVID-19 infection
Slide 18: Strong Cash Position
Strong Cash Position • As of September 30, 2022 Company’s cash balance was approximately $19.6 million • No debt • NASDAQ: AEMD ~22.9 million shares outstanding • Current market cap ~$11 million 18
Slide 19: Summary
Summary ▪ Unique Hemopurifier blood purification device ▪ Experienced management team; strong cash position ▪ Two FDA Breakthrough Device designations ▪ Planned and ongoing international clinical trials ▪ Multiple therapeutic targets in cancer and viral disease ▪ Demonstrated virus and exosome clear
Slide 20: 11555 Sorrento Valley Road, Suite 203 San Diego, California 92121
11555 Sorrento Valley Road, Suite 203 San Diego, California 92121 619.941.0360 Nasdaq: AEMD www.AethlonMedical.com This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully
Aethlon Medical — Sequire Biotechnology Conference 2023 on 6ix